| 25 May 2026 |
4-AP (4-anilino-piperidine / N-phenyl-4-piperidinamine) CAS 23056-29-3 |
5.1 |
500g |
468.5g |
-6.3% |
97.18% |
Lab G |
| 25 May 2026 |
N-Acetyl Epitalon Amidate |
4.0 |
30mg |
37.1mg |
+23.7% |
95.80% |
Lab A |
| 24 May 2026 |
BAC Water |
4.0 |
30mg |
32.6mg |
+8.5% |
98.26% |
Lab B |
| 24 May 2026 |
Bronchogen |
5.0 |
20mg |
21.7mg |
+8.5% |
97.34% |
Lab D |
| 24 May 2026 |
MGF |
4.0 |
10mg |
8.8mg |
-12.5% |
98.36% |
Lab C |
| 24 May 2026 |
MT-1 |
4.0 |
50mg |
48.8mg |
-2.3% |
98.87% |
Lab A |
| 24 May 2026 |
PMK glycidic acid (3,4-MDP-2-P methyl glycidic acid / sodium salt) CAS 1369021-80-6 |
7.9 |
1g |
1.1g |
+7.4% |
99.59% |
Lab F |
| 24 May 2026 |
Vesugen |
4.4 |
10mg |
11.8mg |
+18.2% |
95.49% |
Lab D |
| 24 May 2026 |
Fluoxymesterone (Halotestin) Raw |
4.6 |
500g |
451.0g |
-9.8% |
97.18% |
Lab A |
| 24 May 2026 |
GHK-CU 2000mcg+Glutathione 200mg+Histidine 100mg+Glycine 50mg+NADH 50mg |
5.8 |
200mg/ml |
173.1mg/ml |
-13.4% |
99.53% |
Lab E |
| 24 May 2026 |
Bronchogen |
4.0 |
20mg |
19.1mg |
-4.7% |
98.20% |
Lab C |
| 24 May 2026 |
N-Acetyl Epitalon Amidate |
4.4 |
50mg |
52.6mg |
+5.3% |
96.31% |
Lab D |
| 24 May 2026 |
4-AP (4-anilino-piperidine / N-phenyl-4-piperidinamine) CAS 23056-29-3 |
4.0 |
1g |
1.1g |
+13.6% |
96.52% |
Lab B |
| 24 May 2026 |
MGF |
4.5 |
2mg |
2.0mg |
-1.9% |
96.38% |
Lab E |
| 24 May 2026 |
SR9009 |
5.3 |
20mg |
21.6mg |
+8.1% |
98.60% |
Lab G |
| 24 May 2026 |
Sustanon 250 |
4.0 |
300mg/ml |
274.7mg/ml |
-8.4% |
97.81% |
Lab B |
| 24 May 2026 |
Estradiol Cypionate |
4.0 |
300mg/ml |
318.7mg/ml |
+6.2% |
95.54% |
Lab B |
| 23 May 2026 |
DSIP |
4.0 |
2mg |
2.0mg |
+0.9% |
98.68% |
Lab F |
| 23 May 2026 |
GHRP-2 Acetate |
4.0 |
20mg |
20.7mg |
+3.3% |
98.57% |
Lab A |
| 21 May 2026 |
DSIP |
4.3 |
10mg |
9.2mg |
-7.8% |
98.13% |
Lab C |
| 21 May 2026 |
Finasteride |
4.0 |
20mg |
23.4mg |
+17.2% |
99.42% |
Lab C |
| 21 May 2026 |
AA Water |
4.1 |
10mg |
9.6mg |
-4.3% |
99.35% |
Lab G |
| 21 May 2026 |
BPC-157 Arg Oral |
4.8 |
100mg |
115.6mg |
+15.6% |
99.54% |
Lab E |
| 21 May 2026 |
T3 (Liothyronine) |
4.0 |
100mg |
93.9mg |
-6.1% |
98.49% |
Lab C |
| 20 May 2026 |
MOTS-C |
4.0 |
50mg |
52.7mg |
+5.5% |
96.17% |
Lab D |
| 19 May 2026 |
GHRP-2 Acetate |
4.8 |
30mg |
25.6mg |
-14.6% |
98.11% |
Lab C |
| 17 May 2026 |
NAD+ 100mg + Mots-C 10mg + 5-Amino 1MQ 10mg Blend |
4.8 |
2mg |
2.3mg |
+15.4% |
99.17% |
Lab D |
| 17 May 2026 |
T3 (Liothyronine) |
4.0 |
20mg |
24.6mg |
+23.1% |
98.68% |
Lab E |
| 29 Jan 2026 |
AICAR |
4.9 |
20mg |
18.5mg |
-7.6% |
98.47% |
Lab E |
| 29 Jan 2026 |
BPC157 10mg + TB500 10mg Blend |
5.0 |
30mg |
27.4mg |
-8.8% |
98.98% |
Lab B |
| 26 Jan 2026 |
BPC-157 Arg Oral |
7.0 |
25mg |
25.9mg |
+3.6% |
99.69% |
Lab G |
| 26 Jan 2026 |
DSIP |
4.0 |
10mg |
12.1mg |
+20.7% |
96.33% |
Lab C |
| 26 Jan 2026 |
Retatrutide 30mg Pen Kit |
7.1 |
20mg |
23.3mg |
+16.4% |
95.24% |
Lab G |
| 26 Jan 2026 |
YK11 |
4.8 |
10mg |
9.5mg |
-5.0% |
97.69% |
Lab C |
| 19 Jan 2026 |
GHK-CU 2000mcg+Glutathione 200mg+Histidine 100mg+Glycine 50mg+NADH 50mg |
4.4 |
200mg/ml |
173.9mg/ml |
-13.0% |
99.72% |
Lab C |
| 9 Jan 2026 |
N-Acetyl Epitalon Amidate |
4.9 |
2mg |
2.1mg |
+7.3% |
97.86% |
Lab C |
| 7 Jan 2026 |
NAD+ Injectable |
4.0 |
200mg/ml |
232.4mg/ml |
+16.2% |
99.17% |
Lab E |
| 6 Jan 2026 |
MOTS-C |
4.0 |
20mg |
19.7mg |
-1.7% |
98.76% |
Lab A |
| 29 Dec 2025 |
4-AP (4-anilino-piperidine / N-phenyl-4-piperidinamine) CAS 23056-29-3 |
4.5 |
10g |
9.9g |
-0.6% |
95.38% |
Lab C |
| 29 Dec 2025 |
Dianabol Raw |
6.2 |
100g |
97.3g |
-2.7% |
97.02% |
Lab F |
| 29 Dec 2025 |
Estradiol Cypionate |
4.0 |
300mg/ml |
277.9mg/ml |
-7.4% |
99.94% |
Lab A |
| 29 Dec 2025 |
GHK-CU 2000mcg+Glutathione 200mg+Histidine 100mg+Glycine 50mg+NADH 50mg |
5.0 |
250mg/ml |
265.3mg/ml |
+6.1% |
96.26% |
Lab D |
| 29 Dec 2025 |
GHRP-2 Acetate |
4.5 |
50mg |
46.4mg |
-7.1% |
97.07% |
Lab E |
| 29 Dec 2025 |
IGF-1 LR3 |
4.6 |
5mg |
4.6mg |
-7.1% |
97.78% |
Lab D |
| 29 Dec 2025 |
NAD+ 100mg + Mots-C 10mg + 5-Amino 1MQ 10mg Blend |
4.3 |
10mg |
12.3mg |
+23.4% |
99.74% |
Lab A |
| 12 Dec 2025 |
ACE-031 |
4.0 |
10mg |
11.6mg |
+16.4% |
97.00% |
Lab C |
| 12 Dec 2025 |
Adipotide |
4.9 |
30mg |
26.1mg |
-13.0% |
98.87% |
Lab D |
| 12 Dec 2025 |
BAC Water |
5.8 |
2mg |
2.3mg |
+15.7% |
98.12% |
Lab A |
| 12 Dec 2025 |
Epithalon |
4.1 |
10mg |
9.4mg |
-5.5% |
97.03% |
Lab G |
| 5 Dec 2025 |
5-amino-1MQ |
4.0 |
15mg |
14.7mg |
-2.2% |
99.78% |
Lab B |
| 5 Dec 2025 |
Epithalon |
4.6 |
5mg |
4.3mg |
-13.2% |
98.05% |
Lab B |
| 5 Dec 2025 |
Finasteride |
5.0 |
50mg |
53.5mg |
+7.1% |
98.89% |
Lab F |
| 5 Dec 2025 |
IGF-1 LR3 |
4.0 |
2mg |
2.0mg |
-0.0% |
97.44% |
Lab D |
| 5 Dec 2025 |
Sustanon 250 |
4.5 |
200mg/ml |
182.0mg/ml |
-9.0% |
95.91% |
Lab C |
| 23 Nov 2025 |
AA Water |
6.1 |
30mg |
32.0mg |
+6.8% |
97.56% |
Lab F |
| 23 Nov 2025 |
BPC-157 Arg Oral |
4.2 |
20mg |
24.4mg |
+21.9% |
98.20% |
Lab E |
| 23 Nov 2025 |
Estradiol Cypionate |
4.8 |
200mg/ml |
228.9mg/ml |
+14.5% |
99.73% |
Lab C |
| 23 Nov 2025 |
Finasteride |
4.0 |
25mg |
25.9mg |
+3.6% |
95.41% |
Lab E |
| 23 Nov 2025 |
Fluoxymesterone (Halotestin) Raw |
5.8 |
1g |
1.0g |
-4.0% |
96.80% |
Lab F |
| 17 Nov 2025 |
Adipotide |
4.0 |
15mg |
17.6mg |
+17.3% |
98.49% |
Lab C |
| 17 Nov 2025 |
NAD+ 100mg + Mots-C 10mg + 5-Amino 1MQ 10mg Blend |
4.0 |
50mg |
59.7mg |
+19.5% |
97.90% |
Lab G |
| 17 Nov 2025 |
YK11 |
5.2 |
100mg |
99.6mg |
-0.4% |
95.65% |
Lab B |
| 14 Nov 2025 |
IGF-1 LR3 |
4.0 |
2mg |
2.1mg |
+7.0% |
97.69% |
Lab G |
| 5 Nov 2025 |
AICAR |
4.0 |
10mg |
11.9mg |
+18.6% |
98.44% |
Lab A |
| 5 Nov 2025 |
BAC Water |
6.0 |
10mg |
10.7mg |
+7.3% |
99.12% |
Lab E |
| 5 Nov 2025 |
IGF-1 LR3 |
4.0 |
2mg |
1.8mg |
-12.0% |
96.09% |
Lab B |
| 5 Nov 2025 |
T3 (Liothyronine) |
4.9 |
20mg |
18.2mg |
-9.0% |
97.26% |
Lab A |
| 4 Nov 2025 |
Adipotide |
4.0 |
50mg |
44.1mg |
-11.8% |
95.03% |
Lab C |
| 4 Nov 2025 |
AICAR |
4.0 |
10mg |
12.2mg |
+22.3% |
98.41% |
Lab F |
| 4 Nov 2025 |
Epithalon |
4.0 |
20mg |
21.1mg |
+5.7% |
95.83% |
Lab D |
| 4 Nov 2025 |
T3 (Liothyronine) |
4.0 |
50mg |
51.5mg |
+3.0% |
99.33% |
Lab G |
| 17 Oct 2025 |
ACE-031 |
4.6 |
30mg |
29.0mg |
-3.4% |
96.63% |
Lab F |
| 17 Oct 2025 |
AICAR |
4.6 |
15mg |
16.9mg |
+12.6% |
95.21% |
Lab G |
| 17 Oct 2025 |
Bronchogen |
6.2 |
20mg |
18.2mg |
-8.8% |
97.26% |
Lab C |
| 17 Oct 2025 |
Bronchogen |
4.0 |
5mg |
5.8mg |
+15.6% |
98.64% |
Lab F |
| 17 Oct 2025 |
PMK glycidic acid (3,4-MDP-2-P methyl glycidic acid / sodium salt) CAS 1369021-80-6 |
4.5 |
500g |
523.8g |
+4.8% |
98.30% |
Lab A |
| 17 Oct 2025 |
Vesugen |
4.0 |
5mg |
5.9mg |
+17.2% |
96.71% |
Lab A |
| 9 Oct 2025 |
MT-1 |
5.2 |
2mg |
2.3mg |
+17.5% |
97.17% |
Lab C |
| 9 Oct 2025 |
SR9009 |
4.0 |
100mg |
116.9mg |
+16.9% |
99.18% |
Lab E |
| 3 Oct 2025 |
GHK-CU 2000mcg+Glutathione 200mg+Histidine 100mg+Glycine 50mg+NADH 50mg |
4.0 |
300mg/ml |
363.2mg/ml |
+21.1% |
96.06% |
Lab A |
| 3 Jul 2025 |
Retatrutide |
5.4 |
5mg |
4.91mg |
-1.8% |
98.39% |
Lab E |
| 15 May 2025 |
BPC-157 |
5.0 |
5mg |
4.86mg |
-2.8% |
96.97% |
Lab A |
| 14 May 2025 |
Ipamorelin |
2.0 |
5mg |
3.4mg |
-32.0% |
98.16% |
Lab A |
| 27 Mar 2025 |
Retatrutide |
0.0 |
10mg |
⚠️ Sample does not contain Retatrutide ? |
(no batch ID) |
No Label / Silver Crimp / White caps |
|
| 27 Mar 2025 |
Retatrutide |
0.0 |
10mg |
⚠️ Sample does not contain Retatrutide ? |
(no batch ID) |
No Label / Silver Crimp / White caps |
|
| 27 Mar 2025 |
Retatrutide |
0.0 |
10mg |
⚠️ Sample does not contain Retatrutide ? |
(no batch ID) |
No Label / Silver Crimp / White caps |
|
| 25 Mar 2025 |
Semaglutide |
7.3 |
5mg |
5.35mg |
+7.0% |
99.91% |
Lab C |